GV Research Platform

26/05/2023

Publication alert!

In a recent publication, Envigo ++++’s ICR (CD-1®) outbred mice were used as preclinical pain models to study how activation of MNK-eIF4E signaling effects hypersensitivity and migraine pain. The study suggested that inhibiting the MNK signaling pathway may have significant therapeutic potential as a treatment for migraine.

Please read the following article for more details –
https://www.inotivco.com/model/hsd-icr-cd-1

To understand more on “ICR (CD-1®) outbred" strain of mice, visit -
https://pubmed.ncbi.nlm.nih.gov/36299248/

GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform (GVRP) is a Hyderabad based pre-clinical CRO and an authorized breeder and distributor of Envigo ++++'s research models & services in India.

Reach us for more information:
📨: info@gvrp.in
🌐: www.gvrp.in

26/05/2023

Enhance your research outcomes by partnering with us for your preclinical studies!

GV Research Platform (GVRP) offers a wide range of GLP and non-GLP services in compliance with prominent regulatory bodies, that can assist you advance your drug research outcomes.

With our committed team of experts in Pharmacology, DMPK, Regulatory Toxicology, Analytical and Bio-analytical services, GV Research Platform (GVRP) is a trusted and comprehensive partner for your drug discovery research. Our in-vivo studies are conducted using top-notch research models that possess well-documented health and genetic backgrounds.

Our state-of-the-art, CPCSEA certified vivarium spread across 28,000 sq.ft. supports the commercial breeding and testing operations. This enables us to provide you a dynamic array of drug discovery services of globally recognized quality.

To know more and discuss how we can help you, write to us at info@gvrp.in or visit www.gvrp.in

12/04/2023

Ready for a dose of innovation? Discover how cutting-edge tech is disrupting the Pharma Industry!

The Indian biopharma industry is poised for significant growth, thanks to the adoption of cutting-edge technologies like Humanized models, iPSC technology, precision medicine, patient-derived xenografts, organoids, and AI and machine learning in drug discovery. These technologies have enabled researchers to develop drugs that are more targeted, effective, and personalized, leading to better patient outcomes. (https://lnkd.in/gnDdFTKu)

The use of AI and machine learning in drug discovery is a promising area that can help researchers identify new drug targets and predict the efficacy of drugs with greater accuracy. Patient-derived xenografts, iPSC Technology and Organoids are also promising technologies that can help researchers develop drugs that are more effective against specific types of cancer and other diseases. Using these technologies also help you obtain data that translates to clinically relevant information better.

Discover how these game-changing technologies are revolutionizing healthcare: https://gvrp.in/latest-technologies-shaping-the-world-of-drug-discovery-and-development/

The digitalization of the industry, however, is still in its early stages and requires more investment in research and development. The industry needs to focus on developing innovative drugs that can address unmet medical needs and diseases that are prevalent in India and other developing countries.

The future of medicine is exciting and there's no better time to join the conversation and explore the possibilities.

Don't miss out on the medicine of tomorrow. Read the full blog here: https://gvrp.in/latest-technologies-shaping-the-world-of-drug-discovery-and-development/

GVRP takes pride in bringing these leading technologies from all over the world!
-Explore humanized models with our partner Envigo ++++,
-Patient Derived Xenografts and Organoids with our partner Crown Bioscience , and
-The potential of iPSC technology with our partner NEXEL

We strongly encourage you to learn more about these innovative technologies, which have the potential to revolutionize drug discovery and development.

Contact GV Research Platform (GVRP) to obtain more information about our partners and how they can benefit your research and development efforts.

Reach us for more information:
📨: info@gvrp.in
🌐: www.gvrp.in




.

02/04/2023

Are you still confused whether human derived iPSC cardiomyocytes, hepatocytes, and neurocytes can add value to your research?

Check out our latest blog on the game-changing impact of Human-induced pluripotent stem cell (iPSC) technology in drug discovery and toxicity testing.

iPSC-derived cells have the potential to accelerate drug discovery, reduce the risk of drug failures during clinical development, and ultimately benefit patients and society.

Read full blog here: https://gvrp.in/revolutionizing-drug-discovery-and-toxicity-testing-with-ipsc-technology-an-overview-and-potential-impact/

Our partnership with NEXEL is set to overcome the lack of access to high-quality iPSC cell lines in India, paving the way for revolutionary advancements in iPSC technology.

Join us in accelerating innovation in the Indian biopharma sector!

23/03/2023

Alone we can do so little, together we can do so much.

We are delighted to announce that GV Research Platform (GVRP) has partnered with NEXEL, two innovative leaders in the biomedical industry.

NEXEL is a leading specialist in induced pluripotent stem cell (iPSC) technology. Headquartered in South Korea, NEXEL manufactures iPSC-derived cardiomyocytes, hepatocytes, and neurocytes for drug discovery, toxicity testing, disease modeling, and regenerative medicine. Through this collaboration, GV Research Platform (GVRP) will distribute Nexel's cell lines and associated culture media in India, bringing advanced technology to the forefront of research and development in the region.

This partnership is a major breakthrough for the biomedical community in India. The use of iPSC-derived cells has immense potential to revolutionize drug discovery, toxicity testing, disease modeling, and regenerative medicine, and they provide a more relevant and physiologically accurate model for testing the efficacy and safety of new compounds.

This collaboration will enable the Indian biomedical community to access this innovative technology, accelerating the advancement of biomedical research in the region.

Reach us for more information:
📨: info@gvrp.in
🌐: www.gvrp.in

23/03/2023

We are pleased to welcome aboard Dr. Anil Gothi, DVM, MVSc, ERT, DABT as the Vice-President of GV Safety Assessment Platform!

Dr. Anil is board certified Toxicologist - DABT (Diplomate of the American Board. of Toxicology) and ERT (European Registered Toxicologist). He has been instrumental in the successful IND submissions and in obtaining and maintaining AAALACi, OECD-GLP, and NABL certifications. Dr. Gothi has a strong knowledge of regulatory requirements for non-clinical studies for various substances, such as NCEs, impurities, API, metabolites, nutraceuticals, biosimilars, vaccines, agrochemicals, medical devices, and industrial chemicals, for submissions to various regulatory bodies. He is efficient in project management and has collaborated with cross-functional departments to achieve project objectives. Additionally, he has been involved in strategic business operations to ensure maximum profitability. Dr. Gothi has also played an integral role in safety studies for discovery collaborative/ service projects with multinationals in the US and Europe.

GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform (GVRP) is a Hyderabad based Preclinical CRO and an Authorized breeder and distributor of Envigo’s research products & services in India.

To learn more about the research models and services from GVRP, visit us at - https://gvrp.in/

For enquiries, write to us at info@gvrp.in

02/03/2023

Do you want to learn more about the critical role that preclinical testing plays in ensuring the safety and efficacy of new drugs?

Look no further than our recent blog post!

In this informative and engaging piece, we delve into the world of preclinical testing and explore the unique benefits of both in vivo and in vitro testing methods.

Rather than pitting these methods against each other, we celebrate their unique strengths and demonstrate how they can be effectively incorporated into the drug development process.

But that's not all - we also highlight some of the most exciting advancements in preclinical testing technology, from cutting-edge in vitro models to innovative in vivo techniques.

At GV Research Platform (GVRP), we understand the importance of staying on top of advancing technologies in preclinical testing. Our partnerships with Envigo ++++ and Crown Bioscience allow us to continue to make strides in this field. From the latest in in-vivo and in-vitro testing technologies to the unique benefits of each method, our blog covers it all.

Whether you're a seasoned researcher or simply curious about the world of drug discovery, our blog post has something for everyone.

So why wait? Dive into the fascinating world of preclinical testing today and read the full article at https://gvrp.in/pre-clinical-testing-methods/

28/02/2023

On National Science Day 2023, GV Research Platform (GVRP) celebrates the power of 'Global Science for Global Wellbeing'.

As a leading research platform, GVRP is committed to advancing scientific discovery and innovation to address some of the world's most pressing challenges. Through cutting-edge research and development, we are making significant contributions to the fields of biotechnology and healthcare, driving progress towards a healthier, more sustainable future for all.

28/02/2023

It was a pleasure exhibiting at BioAsia: The Global Biobusiness Forum! The platform gave us an abundant opportunity to discover possibilities, showcase our partnerships and establish successful associations.

GV Research Platform (GVRP) BioAsia Hyderabad Government of Telangana Telangana State Innovation Cell

25/02/2023

An incredible day 1 interacting with dignitaries, executives, and enthusiasts from the industry.

Looking forward to yet another amazing day 2.

See you at Booth No. M50!

Explore a wide range of preclinical offerings from our partners - Envigo Crown Bioscience Inc. NEXEL

https://gvrp.in/

BioAsia: The Global Biobusiness Forum Government of Telangana Telangana State Innovation Cell

23/02/2023

Discover how GV Research Platform (GVRP) can enable you accelerate your research!

We are pleased to announce our participation as an exhibitor at BioAsia: The Global Biobusiness Forum 2023, HICC Hyderabad.

See you at Booth No. M50!

Explore a wide range of preclinical offerings from our partners - Envigo ++++ Crown Bioscience Inc. NEXEL

BioAsia 2023 Government of Telangana on Cell Lifesciences and Pharma Telangana

We are happy to have GV Research Platform as our Exhibitor for the 20th edition of .

Date: 24th-26th February
Location: HICC, Hyderabad

Register today - 2023.bioasia.in

EY Shakthi Nagappan

08/02/2023

Publication alert!

A recent publication used Fmr1 knockout rats (HsdSage:SD-Fmr1+/-em1Sage) from Envigo ++++ to evaluate the behavioral effects of inhibiting phosphodiesterase 2A (PDE2A).

Please read the following article for more details: https://www.nature.com/articles/s41398-022-01885-2

To understand more on "HsdSage:SD-Fmr1+/-em1Sage" strain, please read the following: https://www.envigo.com/model/hsdsage-sd-fmr1-em1sage

GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform is a Hyderabad based pre-clinical CRO and an authorized breeder and distributor of Envigo's research models & services in India.

Reach us for more information:
📨: info@gvrp.in
🌐: www.gvrp.in